The renal renin-angiotensin system plays a major role in determining the rate of chronic renal disease progression. Treatment with activators of the vitamin D receptor retards the progression of experimental chronic renal disease, and vitamin D is known to suppress the renin-angiotensin system in other organs. Here we determined if the beneficial effects of paricalcitol (19-nor 1,25-dihydroxyvitamin D 2 ) were associated with suppression of renin-angiotensin gene expression in the kidney. Rats with the remnant kidney model of chronic renal failure (5/6 nephrectomy) were given two different doses of paricalcitol thrice weekly for 8 weeks.
The increase in end-stage renal disease constitutes a worldwide public health problem. 1, 2 Irrespective of the primary cause of chronic kidney disease, a reduction in nephron units leads to a progressive loss of the remaining nephrons that, if unchecked, results in end-stage renal disease. The pathophysiology of this process involves a self-maintaining cycle of glomerular and tubulointerstitial (TI) damage whereby the hemodynamic and proinflammatory actions of an activated renal renin-angiotensin system (RAS) has a pivotal role. 3, 4 Hence, therapeutic interventions aiming at blocking angiotensin II (ANG II) activity represent a strategic cornerstone designed to halt the progression of chronic kidney disease. 5 Other treatment approaches have met with varying degrees of success 6 and among them, the potential value of vitamin D and its active metabolites has recently been the matter of considerable interest. In addition to its primary role in calcium homeostasis and bone mineralization, the vitamin D endocrine system has additional physiological functions involving the immune and cardiovascular system and the protection of renal cellular integrity. 7, 8 Most of the pleiotropic actions of vitamin D and its analogues are mediated by the vitamin D receptor (VDR), a liganddependent transcription factor belonging to the steroid nuclear receptor gene family 8 and recent clinical and experimental observations have highlighted the role of the VDR as a downregulator of the RAS. There is an inverse relationship between vitamin D and blood pressure and renin activity, suggesting that vitamin D deficiency may be a cardiovascular risk factor. 9, 10 Mice lacking VDR and mice with inhibited calcitriol synthesis have increased renal mRNA expression of renin, elevated ANG II levels, hypertension and cardiac hypertrophy and, conversely, calcitriol injections suppress renin. 11, 12 In relation to chronic kidney disease, it has been shown that deficiencies of 1,25-dihydroxyvitamin D 3 (calcitriol) may contribute to structural and functional deterioration of the kidney. Several studies have shown that the administration of calcitriol and several of its analogues attenuate the renal damage in various experimental models of uremia, [13] [14] [15] [16] suppress renal inflammation in obstructive uropathy, 17 and reduce the expression of transforming growth factor-b (TGF-b). 18 However, to our knowledge, the potential suppression of genes of the RAS by paricalcitol in the renal ablation model has not been investigated. These effects could be central to the renoprotective effects of this vitamin D analogue and could have implications of considerable clinical significance. The present studies were designed to evaluate this aspect of paricalcitol treatment in rats with 5/6 nephrectomy (5/6 Nx).
RESULTS

Physical parameters, renal function, and blood pressure
The baseline characteristics before surgery are shown in Table 1 . No differences in body weight, blood pressure, plasma creatinine, and urinary protein excretion existed among the groups at the initiation of the experiments.
The systolic blood pressure (SBP) increased markedly in all groups with renal ablation (untreated and paricalcitol treated), and remained significantly higher throughout the experiment compared to values of sham-operated rats ( Figure 1a ). The SBP increment was less pronounced in the nephrectomized rats treated with either paricalcitol dose (P1 and P2 groups, Po0.05 or lower vs the 5/6 Nx group, Figure 1a ).
Plasma creatinine concentrations increased following renal ablation and remained higher compared to values in shamoperated rats throughout the observation period. However, after the second week, creatinine concentrations declined in both paricalcitol-treated groups, and stabilized at levels not significantly different (P ¼ NS) than those in sham-operated rats (final creatinine concentration 0.5 ± 0.04 mg/100 ml) and significantly lower than those in the untreated 5/6 Nx group (final creatinine concentration 1.59 ± 0.16 mg/100 ml) for the Figure 1 | Systemic blood pressure and renal functional determinations in rats with renal ablation. Groups represent untreated (5/6 Nx), treated with low (P1 ¼ 0.1 mg/kg, 3 times per week intraperitoneally) or high-dose paricalcitol (P2 ¼ 0.3 mg/kg, 3 times per week intraperitoneally) and sham-operated rats. (a) The SBP increased in all groups with renal ablation compared to sham rats, but less pronounced in rats treated with either paricalcitol dose (P1 and P2 groups); a, SBP significantly higher than the other groups (Pp0.01), b, Sham-operated rats had lower SBP than the rest (Pp0.05). (b) Plasma creatinine, initially elevated in all groups with renal ablation, promptly declined after the second week in paricalcitol-treated rats to levels comparable to sham rats and significantly lower than in nontreated 5/6 Nx rats. Asterisks (***) represent higher that the rest (Po0.001; a, lower than the rest (Pp0.05). (c) Proteinuria increased progressively in all nephrectomized groups but was distinctly lower in the groups treated with paricalcitol; a, higher than sham and P1 (Pp0.05), b, significantly higher (5/6 Nx) or lower (Sham) than the rest (Pp0.05). Data in the figure are mean ± s.e.
remaining of the study (Po0.01). Final plasma creatinine concentrations were essentially similar in the groups treated with either lower (P1, 0.67 ± 0.04 mg/100 ml) or higher (P2, 0.76 ± 0.07 mg/100 ml) doses of paricalcitol ( Figure 1b ). Sequential determinations of calcium concentrations at 2-week intervals in paricalcitol-treated animals ranged from 8.5 to 10.2 mg/100 ml. The plasma concentrations of Ca were similar in all treated groups but were lower in the sham group (Table 2) . Final phosphorus concentrations were unmodified by paricalcitol treatment and remained at similar levels in all experimental groups ( Table 2 ).
The development of proteinuria was markedly reduced with the administration of paricalcitol ( Figure 1c ). Proteinuria increased progressively in all groups, but was distinctly lower in the groups treated with paricalcitol where by week 8 a reduction 450% occurred compared to the untreated 5/6 Nx group (Po0.01) Anatomical and histological studies Sham-operated rats had an increment (Po0.01) in body weight of 60.5±14.42 g (Table 2 ) from the values at the initiation of the experiment shown in Table 1 . In contrast, body weights did not increase significantly in nephrectomized rats and were similar in P1, P2, and 5/6 Nx groups at the end of the experiment ( Table 2 ). Mean weight values of the remnant kidney at the end of the experiment were essentially similar in the 5/6 Nx, P1, and P2 groups and the estimated hypertrophy during the 8-week post-renal ablation was somewhat lower but not significantly different in the paricalcitol-treated groups ( Table 2 ). Histological studies demonstrated important renoprotection with the administration of paricalcitol, as evidenced by the reduced glomerular sclerosis and TI damage scores in the paricalcitol-treated rats compared to nontreated 5/6 Nx uremic rats ( Table 2 ).
Real-time reverse transcriptase-polymerase chain reaction and protein expression
The mRNA expression and their protein products (western blot) of components of the RAS are shown in Figures 2 and 3 , Table 2 .
respectively. The mRNA expression of angiotensinogen (Figure 2a ), renin ( Figure 2b ), and renin receptor ( Figure  2c ) were significantly reduced by paricalcitol treatment. The suppressive effects of paricalcitol treatment were more prominent for angiotensinogen and renin in the high-dose paricalcitol group (P2). Angiotensin type 1 receptor (AT1R; Figure 2d ) and angiotensin-converting enzyme (ACE; Figure 2e ) mRNAs were not modified by paricalcitol treatment. The mRNA expression of vascular endothelial growth factor (VEGF) was also reduced by paricalcitol treatment (Figure 2f ). Western blot studies demonstrated reduction of the protein expression of renin ( Figure 3a (Figure 3c ).
DISCUSSION
The present study was designed with the hypothesis that paricalcitol abrogates the progressive renal damage and dysfunction associated with renal mass reduction by suppressing genes of the RAS. The novel findings of the study are the demonstration that paricalcitol treatment reduces mRNA levels and protein expression of angiotensinogen, renin, renin receptor, and VEGF in the 5/6 nephrectomized rats in association with the previously known beneficial effects of vitamin D on the histological and functional deterioration of the kidneys.
Vitamin D deficiency occurs early in chronic kidney disease 19 and the administration of active vitamin D in experimental animal models [13] [14] [15] [16] and in clinical trials 20 resulted in attenuation of renal histological abnormalities and improvement of proteinuria 21 or stabilization of renal dysfunction without adverse effects on the progression of renal insufficiency. 20 Previous studies on the renoprotective effects of activated vitamin D focused on its antiproliferative properties in in vitro cell preparations, 22 on the reduction of mesangial proliferation and glomerulosclerosis in the anti-Thy-1 glomerulonephritis, 23 and on the reduced renal expression of TGF-b in the renal ablation model. 13, 14 Kuhlmann et al. 24 identified the podocyte as an important target for the action of 1,25-dihydroxyvitamin D 3 and recent studies by Mizobuchi et al. 18 extended these observations showing that blood pressure control with angiotensinconverting enzyme inhibition amplifies the TGF-mediated renoprotective effects induced by the vitamin D analogue paricalcitol. The present studies confirm the renoprotective effect of paricalcitol in the renal ablation model. The degree of renoprotection and particularly the reduction in proteinuria with paricalcitol in our study is somewhat greater than that found by Hirata et al. 14 using the analogue 22oxacalcitriol, but the studies are not strictly comparable as the renal failure 8 weeks after renal ablation in their study was less severe than in ours. The severity of hypertension observed in the untreated 5/6 Nx group here is similar to previous studies from our laboratory 25 and by others 18 in this model of renal ablation. Both paricalcitol-treated groups displayed significantly lower SBP readings compared to the untreated 5/6 Nx group, and in those treated with the higher paricalcitol dose, the BP did not differ from sham rats (Figure 1a ). Studies in the literature have also reported variable changes in blood pressure as a result of modification in vitamin D activity. In nonuremic VDR-null animals, the increased activity of the RAS is associated with hypertension 11 but in rats with renal mass reduction, Schwarz et al. 13 and Mizobuchi et al. 18 noted that neither calcitriol nor paricalcitol had a significant effect on the SBP, whereas others have noted either modest amelioration, 15 or even increased blood pressure with calcitriol. 26 Probably the conflicting results are related to the opposing interplay between a reduced activity of the RAS and the renal mass reduction which, in turn, engage a multiplicity of mechanisms involved in the pathogenesis of hypertension. 27 The improvement in renal functional parameters ( Figure  1a -c) reflected the histological improvement (Table 2) , as evidenced by the lower glomerular sclerosis index, and in particular the lower score of TI injury in animals that received paricalcitol. These findings are in concordance with the demonstration of inhibition by paricalcitol of TGF-binduced epithelial to mesenchymal transition and myofibroblast accumulation. 17 Overproduction of TGF-b is almost universally observed in models of experimental renal failure, is known to have a crucial role in renal fibrogenesis, and blockade of its activity is associated with attenuation of progressive renal failure. 28, 29 We also noted a marked overexpression of TGF-b in the renal tissues of 5/6 Nx rats that was significantly attenuated by the administration of paricalcitol (Figure 3c ). Other investigators have previously demonstrated pronounced inhibition of the TGF-b mRNA levels in 5/6 Nx rats treated with paricalcitol 18 and in adriamycin-induced renal failure with another VDR analog, 22-oxacalcitriol. 15 The RAS has a central role in causing renal deterioration through hemodynamic, proinflammatory, and profibrotic mechanisms. 28 Our novel observations of a marked reduction in the kidney of the mRNA angiotensinogen, renin, and renin receptor expressions in the paricalcitol-treated groups are of particular relevance in relation to the fact that the local intrarenal RAS may operate independently from and sometimes contrary to its systemic counterpart 30, 31 and that proximal tubular cells actively produce ANG II and secrete angiotensinogen into the tubular lumen. 31 We did not measure plasma renin levels in the present investigations, but the surgical renal ablation model used in this study is typically a low-plasma renin model and therefore systemic RAS activity should not be having a preeminent role in the observed intrarenal RAS changes.
We restricted reverse transcription (RT)-PCR determinations to the animals with renal ablation aiming to focus on the effects of the VDR activator in renal insufficiency; shamoperated animals were not studied. However, previous studies by other investigators have demonstrated by RT-PCR the suppressive effects of calcitriol 11 and paricalcitol 32 on the renal RAS of normal rodents and studies by Gilbert et al. 33 have shown that following subtotal nephrectomy, renin synthesis is suppressed at the juxtaglomerular apparatus but appears de novo in the tubular epithelium accompanied by concomitant de novo appearance of ANG II in the renal tubule. The increase in renin was particularly apparent in areas of marked injury compared with regions in which only mild structural disruption was present. 33 Consistent with their findings, 33 in the present study paricalcitol treatment resulted in reduced renin mRNA expression in association with preservation of TI integrity.
The renal RAS, specifically the renal expression of renin, is known to be mediated by calcium metabolism or parathyroid hormone. 34 Although ionized calcium or parathyroid hormone were not determined in the present experiments, Li et al. 11 have clearly demonstrated that normalization of hypocalcemia and increased parathyroid hormone by dietary intervention in VDR-ablated animals had no effect on the markedly elevated renal renin expression. More recently, administration of paricalcitol to normal mice resulted in a significant suppression of renal renin expression in the absence of hypercalcemia at doses (0.3 mg/kg, like our P2 group) 10-fold above necessary for parathyroid hormone suppression. 32 The doses of paricalcitol employed in our study were non-hypercalcemic 35 as evidenced by the normal total serum Ca concentrations throughout the observation period. High calcium diets can also reduce the expression of RAS components in renal tissues of rats with experimental renal failure, 36 but all animals in the present study were fed a normal Ca intake. In addition, suppression of renal renin expression was evident in both paricalcitol-treated animals compared to the nontreated nephrectomized group despite similar plasma calcium concentrations in all three groups (Table 2) . Thus, we believe that the observed changes in renal RAS genes are unlikely the result of changes in calcium metabolism.
The reduced mRNA levels and protein expression of renin receptor observed in renal tissues of the paricalcitol-treated rats may also offer relevant benefits over other well recognized anti-angiotensin therapies, such as AT1R blockers, which may increase receptor-mediated renin activity. 37 Furthermore, paricalcitol may also suppress the progression of renal damage by mechanisms independent of ANG II as angiotensin-converting enzyme inhibitors and AT1R blockers do not modify the increase in TGF-b synthesis induced by renin. 38 Therefore, paricalcitol administration may provide a dual renoprotective effect, namely by way of reduced ANG II generated through the intrarenal RAS cascade, as well as a result of its direct suppressive effects on the renin receptormediated TGF-b generation. The reduction of the AT1R protein expression does not appear to be related to a paricalcitol-induced downregulation in its mRNA expression. It is possible that protein stability may be affected while mRNA levels remain unchanged. It should be noted that in rats with 5/6 Nx, renal AT1R expression is increased in the TI compartment and, particularly, in the interstitial component, where its expression is reduced by angiotensin receptor blockers and anti-inflammatory agents. 39 Therefore, it is reasonable to assume that the reduction in AT1R obtained with paricalcitol treatment is the result of a lesser interstitial inflammation and expansion resulting from this therapy ( Table 2) . Whether post-translational factors are involved in the reduced AT1R expression cannot be ascertained from the present experiments. Similarly, the suppressed renin expression found in the P1 group (Figure 3 ) while renin mRNA levels were significantly reduced only in the P2 group, are likely due to larger variability in the renin mRNA in the P1 group (Figure 2) .
A special note deserves the new observation that paricalcitol treatment reduces mRNA and protein expression of VEGF in the kidney. In renal disease, VEGF has been reported to have paradoxical effects that have been explained by the uncoupling of its activity to the endothelial nitric oxide axis. 40 This growth factor is prominently expressed in glomerular podocytes and in tubular epithelial cells and its increased expression causes glomerular hypertrophy and proteinuria. 41 In the renal ablation model, inhibition of VEGF results in amelioration of glomerular hypertrophy and reduction of proteinuria. 42 As the synthesis of VEGF is stimulated by ANG II through the activation of the p38 MAPK pathway 43 it is reasonable to suggest that the reduction in VEGF synthesis by paricalcitol is a consequence of the inhibition of the RAS and that VEGF suppression contributed to the histological and functional improvement.
In summary, the present study demonstrates that paricalcitol suppresses genetic expression of key components of the RAS and VEGF in the remnant kidney and confirms that early administration of paricalcitol is capable of halting the otherwise unabated histological and functional deterioration of the kidney.
MATERIALS AND METHODS Experimental animals and design
The studies were performed in male Sprague-Dawley rats [Instituto Venezolano de Investigaciones Científicas (IVIC), Los Teques, Altos de Pipe, Venezuela] that weighed 265-395 g at the beginning of the experiments. They were housed in temperature-controlled facilities, fed standard rat chow (Ratarina, Protinal, Valencia, Venezuela) with free access to water, and handled in accordance with institutional guidelines of animal care. The protocol of the experiments was approved by the Committee of Animal Care and Use of the IVIC-Zulia. Rats were assigned to have either renal ablation by 5/6 Nx or to have a sham operation. Renal ablation was performed by surgical resection of the right kidney and the two poles of the left kidney, and the kidneys and poles removed were weighted immediately. All surgical procedures as well as killing at the end of the experiments were performed under diazepam/ketamine general anesthesia. Postoperative pain was relieved by a protocol administration of a single dose of diazepam (1 ml of a 1 mg/ml solution) after the rat was completely awake after surgery.
Renal ablation has a 20-30% surgical mortality in our laboratories. Four days after surgery, the animals that survived renal ablation were assigned to the following experimental groups : (1) P1 group (n ¼ 10) received paricalcitol 0.1 mg/kg, three times a week by intraperitoneal (i.p.) injection; (b) P2 group (n ¼ 5) received i.p. paricalcitol 0.3 mg/kg at the same intervals. This group was initially of six animals but one animal from this group died in the 8th week before killing and was excluded from analysis; and (3) 5/6 Nx group (n ¼ 10) received vehicle three times a week and (4) Sham-operated group (n ¼ 10) consisted of rats that underwent similar surgical incision, the kidneys were manipulated but left intact and the wound was closed. The doses of paricalcitol employed in the present study have been previously demonstrated to effectively control the development and treatment of secondary hyperparathyroidism without elevations in serum ionized calcium in the 5/6 Nx model 35 and are within the therapeutic dose-range currently used in clinical practice. 44 The administration of paricalcitol or vehicle was begun 5-6 days after surgery and maintained for 8 weeks. Plasma samples for creatinine, calcium, and 24 h urine protein were evaluated every 2 weeks by autoanalyzer methodology as previously described. 25 Weight was determined at the beginning, at 4 weeks, and after 8 weeks and SBP was determined every 2 weeks. At killing, remnant kidneys were harvested, weighted and processed for histology and mRNA determinations. Hypertrophy of the remnant kidney was estimated assuming that the kidney that remained after 5/6 Nx represented 1/6 of the weight of the removed renal tissue.
Blood pressure measurements
The SBP was determined by tail-cuff plethysmography (IITC Life Science Inc., Woodland Hills, CA, USA). As described in previous communications, [45] [46] [47] [48] animals had been preconditioned to the procedure. For this purpose, in 4-5 occasions before the experiments were begun the rats were placed in the restrainer, allowed to rest for 10-15 min in a quiet ambient and the cuff was inflated several times before the animals were returned to their cages. During the experiments, a similar procedure was followed and after stable values were obtained, the average of three determinations of the systolic and mean arterial pressures were recorded.
Renal histology
Paraffin-embedded biopsies stained with periodic acid-Schiff, hematoxylin and eosin, and trichrome stains were used for light microscopy studies. Severity of glomerular sclerosis was evaluated using an index score reported in previous communications [45] [46] [47] [48] by grading glomerular involvement in a scale from 0 (normal) to 4 þ (sclerosis occupying more than 75% of the glomerular tuft) and calculating a score using the following formula: [(1 Â n glomeruli with 1 þ ) þ (2 Â n glomeruli with 2 þ ) þ (3 Â n glomeruli with 3 þ ) þ (4 Â n glomeruli with 4 þ )] Â 100/total number of glomeruli examined. The TI damage was graded as in previous communications [45] [46] [47] [48] according to the extent of damage (infiltration, fibrosis, tubular dilatation) in successively evaluated fields in the entire renal cortex (0 ¼ normal, 1 þ p10%, 2 þ ¼ 10-25%, 3 þ X25-50%, 4 þ X50-75% and 5 þ X75%). All histological studies were performed blinded as to the group in which the biopsy was obtained. Computer-assisted image analysis was performed employing an Olympus BX51 System Microscope (Olympus Corp., Miami, FL, USA) and the DP70 microscope digital camera with Sigma Pro (Leesburgh, VA, USA) image analysis software as in previous work. [49] [50] [51] Real-time PCR PCR studies were performed in remnant kidneys harvested from 5 to 6 rats of each experimental group immediately placed in RNALater solution (Ambion, Austing, TX, USA) to store at À80 1C. Total RNAs were extracted from these tissues using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instruction. First-strand cDNAs were reverse transcribed from total RNAs using MML-V reverse transcriptase (Invitrogen) and hexanucleotide random primers. PCR was performed in an Applied Biosystems 7300 Real-Time PCR System using an SYBR green PCR reagent kit (Applied Biosystems, Foster City, CA, USA), and the change in each mRNA expression was determined based on the formula 2 ÀDDCt ð Þ as previously described. 52 The relative amount of the sample mRNA was normalized to the b 2 -microglobulin mRNA. The PCR primers used in this study are listed in Table 3 .
Western blot
Western blot analyses were performed in paraffin-embedded kidney tissues after extraction according to the method described by Ikeda et al. 53 As the renal functional and histopathological findings were comparable in both paricalcitol-treated groups, protein expression was analyzed by western blotting in the same tissues of the P1 group (n ¼ 5-6) where RT-PCR were measured. As described in a recent publication, 54 kidney homogenates were prepared in lysis buffer (50 mN Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, and 0.1% SDS) containing protease inhibitor. After centrifugation (3000 g for 30 min, 4 1C) protein determination was determined in the supernatant. Samples were resuspended in 25 ml of 60 mM Tris-HCL (containing 25% glycerol, 2% SDS, 14.4 mM 2-mercaptoethanol, and 0.1% bromophenol blue), heated at 65 1C, centrifuged (3000 g for 1 min), loaded on 10% separating gel and eletrophoresed at 100 mV. Proteins were then transferred to nitrocellulose membranes (Bio-Rad). After blocking with nonfat dry milk (5%) in Tris-buffered saline containing 0.1% Tween 20 for 1 h at room temperature, membranes were incubated overnight at 4 1C with the primary antibodies. Membranes were then washed in tris buffersaline (TBS) with 0.1% Tween 20 and incubated with the secondary antibody. Peroxidase activity was developed with 3,3 0 -diaminobenzidine with ion metal enhancement and protein levels were quantified in the Image J program. Primary antibodies used were: anti-b actin polyclonal antibody (Assay Designs, Ann Arbor, MI, USA); anti-renin antibody (G-18; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-renin receptor antibody (K-19; Santa Cruz Biotechnology), anti TGF-b (Promega, Madison, VA, USA), and anti-VEGF (Santa Cruz Biotechnology). Secondary antibodies were horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G (Stressgen Bioreagents, Glanford, Canada) and donkey antigoat (Santa Cruz Biotechnology), all used at 1:1000 dilution in Tris-buffered saline containing 5% dry milk and 0.1% Tween 20.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 4.00 for Windows, GraphPad Software, San Diego, CA, USA. All data are given as mean ± s.e. Comparison between groups was made using one-way multigroup analysis of variance tests followed by Tukey-Kramer post tests. Serial changes were evaluated with repeated-measures analysis of variance and changes with respect to baseline with Dunnett tests. Two-tailed P-values o0.05 were considered significant.
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